Senators want Medicare coverage of lung cancer screen; FDA downgrades pancreatic drainage stent;

@FierceMedDev: Qiagen and Lilly continue successful string of diagnostics partnerships. More | Follow @FierceMedDev

@VarunSaxena2: Medicare will next year have 140,000 different codes, including nine for injuries caused by turkeys. Story from The Economist | Follow @VarunSaxena2

@MichaelGFierce: 'Nanodaisies' carry two cancer drugs and protect them in the bloodstream. Article | Follow @MichaelGFierce

@EmilyWFierce: FDA will hear Sanofi's second plea for Lemtrada approval. Item | Follow @EmilyWFierce

> Senators are urging the Centers for Medicare & Medicaid Services to cover low-dose CT scans for lung cancer screening. Story

> FDA downgraded the regulatory status of pancreatic drainage stents. They can now be cleared via the 510(k) pathway. Story

> FDA allowed the marketing of the first noninvasive test to aid in determining the causes of certain kidney disease. Release

Biotech News

@FierceBiotech: AbbVie heralds early success with its brain cancer-fighting armed antibody. Story | Follow @FierceBiotech

@JohnCFierce: I have to admit, every time I hear something about 'dendritic cells,' I cringe a little. #ASCO14 | Follow @JohnCFierce

@DamianFierce: FT's "usually well informed sources" say $SHPG is eyeing $NPSP. More | Follow @DamianFierce

@EmilyMFierce: BMJ accuses EMA of watering down open trial data policy. Story | Follow @EmilyMFierce

> Can AstraZeneca's cancer pipeline come through on a $12B promise? Story

> Metabolic disease, cardio expert joins Pfizer's R&D team. Chutes & Ladders

Pharma News

@FiercePharma: ICYMI yesterday: The top 10 best-selling vaccines of 2013. Report | Follow @FiercePharma

@TracyStaton: ICYMI, FiercePharma's top weekend news: FDA-nixed diabetes med from Lilly, Boehringer faces rough path to stardom. More | Follow @TracyStaton

@CarlyHFierce: Study: Moral concerns lead barriers to Gardasil uptake in college freshmen. Story from FierceVaccines | Follow @CarlyHFierce

> ASCO tackles a tough question: When is a cancer drug too pricey? More

> Forest spills on Actavis deal details as part of shareholder settlement. Story

> District judge green-lights kickback lawsuit against Novartis. News

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.